Fiona A. Chapman

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Targeting the apelin system for the treatment of cardiovascular diseases

Fiona A. Chapman, Janet J. Maguire, David E. Newby et al. · Cardiovascular Research · 2023 · 72 citations · Full text

Hypertension: Current trends and future perspectives

Paul G. Hunter, Fiona A. Chapman, Neeraj Dhaun · British Journal of Clinical Pharmacology · 2021 · 51 citations · Full text

Polygenic risk score as a determinant of risk of non-melanoma skin cancer in a European-descent renal transplant cohort

Caragh P. Stapleton, Kelly A. Birdwell, Amy Jayne McKnight et al. · American Journal of Transplantation · 2018 · 42 citations · Full text